Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All zinc studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchZincZinc (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 65% Improvement Relative Risk Zinc for COVID-19  Elavarasi et al.  LATE TREATMENT Is late treatment with zinc beneficial for COVID-19? Retrospective 1,687 patients in India (April - June 2021) Lower mortality with zinc (p=0.0000016) c19early.org Elavarasi et al., Lung India, August 2021 Favors zinc Favors control

Clinical features, demography, and predictors of outcomes of SARS-CoV-2 infection at a tertiary care hospital in India: A cohort study

Elavarasi et al., Lung India, doi:10.4103/lungindia.lungindia_493_21
Aug 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Zinc for COVID-19
2nd treatment shown to reduce risk in July 2020
 
*, now known with p = 0.0000013 from 44 studies, recognized in 10 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19early.org
Retrospective 2017 hospitalized patients in India, showing lower mortality with zinc treatment.
Study covers ivermectin, zinc, and remdesivir.
risk of death, 65.1% lower, RR 0.35, p < 0.001, treatment 486, control 1,201, adjusted per study, odds ratio converted to relative risk, model 4, multivariate logistic regression, control prevalence approximated with overall prevalence.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Elavarasi et al., 12 Aug 2021, retrospective, India, peer-reviewed, 31 authors, study period April 2021 - June 2021.
This PaperZincAll
Clinical features, demography, and predictors of outcomes of SARS-CoV-2 infection at a tertiary care hospital in India: A cohort study
Dr Sushma Bhatnagar, Arunmozhimaran Elavarasi, Harikrishna Raju Sagiraju, Rohitkumar Garg, Brajesh Ratre, Prashant Sirohiya, Nishkarsh Gupta, Rakesh Garg, Anuja Pandit, Saurabh Vig, Ram Singh, Balbir Kumar, Vedprakash Meena, Naveet Wig, Saurabh Mittal, Sourabh Pahuja, Karan Madan, Randeep Guleria, Anant Mohan, Tanima Dwivedi, Ritu Gupta, Ashimajain Vidyarthi, Rama Chaudhry, Arghya Das, Laxmitej Wundavalli, Angelrajan Singh, Sheetal Singh, Sunil Kumar, Manisha Pandey, Abhinav Mishra, Karanvirsingh Matharoo
Lung India, doi:10.4103/lungindia.lungindia_493_21
Background: The "second wave" of the COVID-19 pandemic hit India from early April 2021 to June 2021. We describe the clinical features, treatment trends, and baseline laboratory parameters of a cohort of patients with SARS-CoV-2 infection and their association with the outcome. Methods: This was a retrospective cohort study. Multivariate logistic regression models were fitted to identify clinical and biochemical predictors of developing hypoxia, deterioration during the hospital stay, and death. Results: A total of 2080 patients were included. The case fatality rate was 19.5%. Among the survivors, the median duration of hospital stay was 8 (5-11) days. Out of 853 (42.3%%) of patients who had COVID-19 acute respiratory distress syndrome at presentation, 340 (39.9%) died. Patients aged >45 years had higher odds of death as compared to the 18-44 years age group. Vaccination reduced the odds of death by 40% (odds ratio [OR] [95% confidence interval [CI]]: 0.6 [0.4-0.9], P = 0.032). Patients with hyper inflammation at baseline as suggested by leukocytosis (OR [95% CI]: 2.1 [1.5-3.1], P < 0.001), raised d-dimer >500 mg/dL (OR [95% CI]: 3.2 [2.2-4.7], P < 0.001), and raised C-reactive peptide >0.5 mg/L (OR [95% CI]: 3.7 [2.2-13], P = 0.037) had higher odds of death. Patients who were admitted in the 2 nd week had lower odds and those admitted in the 3 rd week had higher odds of death.
Conflicts of interest There are no conflicts of interest. 1.2 (0.9-1.6), 0.199 1 (0.7-1.5), 0.980 1 (0.6-1.7), 0.943 1.1 (0.7-1.9), 0.708 Primary condition (Reference: COVID) Non-COVID 3.5 (1.7-7.2), 0.001 1.2 (0.4-3.5), 0.705 0.8 (0.3-2•6), 0.729 0.5 (0.1-1.8), 0.266 Mucor 0.5 (0.1-4.0), 0.472 0.9 (0.1-11), 0.940 Vaccinated 0.7 (0.5-1.0), 0.060 0.6 (0.4-0.9), 0.032 0.5 (0.3-0.9), 0.014 0.6 (0.3-0.9), 0.042 Symptom onset to hospitalization (Reference: 1 week) 2 weeks 0.6 (0.5-0.9), 0.003 0.6 (0.4-0.9), 0.027 0.5 (0.3-0.8), 0.002 0.5 (0.3-0.8), 0.003 3 or more weeks 1.9 (1.1-3.4), 0.032 0.9 (0.4-2.2), 0.828 0.6 (0.2-1.9), 0.372 0.5 (0.1-1.9), 0.336 Asymptomatic 1.1 (0.
References
Aggarwal, Shrivastava, Kumar, Ali, Clinical and epidemiological features of SARS-CoV-2 patients in SARI ward of a tertiary care centre in New Delhi, J Assoc Physicians India
Albalawi, Alharbi, Bakouri, Alqahtani, Alanazi et al., Clinical characteristics and predictors of mortality among COVID-19 patients in Saudi Arabia, J Infect Public Health
Ards Definition, Force, Ranieri, Rubenfeld, Thompson et al., Acute respiratory distress syndrome: The Berlin Definition, JAMA
Bairwa, Kumar, Ajmal, Bahurupi, Kant, Predictors of critical illness and mortality based on symptoms and initial physical examination for patients with SARS-CoV-2: A retrospective cohort study, J Infect Public Health
Bellani, Laffey, Pham, Brochard, Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in Intensive Care Units in 50 countries, JAMA
Chauhan, Shadrach, Garg, Bhatia, Bhardwaj et al., Predictors of clinical outcomes in adult COVID-19 patients admitted to a tertiary care hospital in India: An analytical cross-sectional study, Acta Biomed
Gregoriano, Koch, Haubitz, Conen, Fux et al., Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: An observational analysis, Swiss Med Wkly
Gupta, Ish, Kumar, Dev, Yadav et al., Evaluation of the clinical profile, laboratory parameters and outcome of two hundred COVID-19 patients from a tertiary centre in India, Monaldi Archives for Chest Disease, doi:10.4081/monaldi.2020.1507
Mohan, Tiwari, Bhatnagar, Patel, Maurya et al., Clinico-demographic profile & hospital outcomes of COVID-19 patients admitted at a tertiary care centre in North India, Indian J Med Res
Sagiraju, Elavarasi, Gupta, Garg, Paul et al., The effectiveness of SARS-CoV-2 vaccination in preventing severe illness and death-real-world data from a cohort of patients hospitalized with COVID-19, medRxiv, doi:10.1101/2021.08.26.21262705
Sirohiya, Elavarasi, Sagiraju, Baruah, Gupta et al., Silent hypoxia in coronavirus disease-2019: Is it more dangerous? -A retrospective cohort study, medRxiv, doi:10.1101/2021.08.26.21262668
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA
Zhang, Cao, Tan, Dong, Wang et al., Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients, Allergy
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit